Quantifying Antigen-Specific T Cell Responses When Using Antigen-Agnostic Immunotherapies.

ABSTRACT: Immunotherapies are at the forefront of the fight against cancers, and researchers continue to develop and test novel immunotherapeutic modalities. Ideal cancer immunotherapies induce a patient's immune system to kill their own cancer and develop long-lasting immunity. Research has demonstrated a critical requirement for CD8⁺ and CD4⁺ T cells in achieving durable responses. In the path to the clinic, researchers require robust tools to effectively evaluate the capacity for immunotherapies to generate adaptive anti-tumor responses. To study functional tumor-specific T cells, researchers have relied on targeting tumor-associated antigens (TAAs) or the inclusion of surrogate transgenes in pre-clinical models, which facilitate detection of T cells by using the targeted an

SUBMITTER: van Vloten JP 

PROVIDER: S-EPMC6369252 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature